Skip to main content
. 2023 Feb 28;13:3392. doi: 10.1038/s41598-023-28438-x

Table 4.

Clinical and functional outcomes in the 2 groups without and with Stenotrophomonas infection.

Statistic Stenotrophomonas Test OR (95% CI) p value
No (103 patients) Yes (20 patients)
Mortality
 N N (%) 62 (60.2%) 8 (40%) FFH 0.161
 COVID-19-related N (%) 37 (35.9%) 11 (55%)
 Not COVID-19-related N (%) 4 (3.9%) 1 (5%)
Length of stay Me [IQR] 20 [13–29] 34 [22–82.5] MWU 0.000
Prone position N (%) 53 (52.5%) 13 (68.4%) Chi2 1.96 (0.69–5.57) 0.200
Thromboembolic event N (%) 12 (11.8%) 3 (15%) Chi2 1.32 (0.34–5.19) 0.687
Hemorrhagic event N (%) 12 (11.7%) 6 (30%) Chi2 3.25 (1.05–10.06) 0.034
Day of Hemorrhagic event Me [IQR] 17.5 [10.5–21] 20 [14–31] MWU 0.511
Intubation N (%) 55 (53.4%) 19 (95%) Chi2 16.6 (2.14–128.5) 0.001
Discharge status
 Autonomous N (%) 31 (49.2%) 1 (14.3%) MWU 0.038
 O2 N (%) 27 (42.9%) 4 (57.1%)
 Ventilation N (%) 2 (3.2%) 0 (0%)
 Tracheostomy N (%) 3 (4.8%) 2 (28.6%)
PCFS at discharge
 0 N (%) 10 (14.7%) 7 (50%) MWU 0.242
 1 N (%) 7 (10.3%) 0 (0%)
 2 N (%) 19 (27.9%) 1 (7.1%)
 3 N (%) 14 (20.6%) 2 (14.3%)
 4 N (%) 18 (26.5%) 4 (28.6%)
2-month post-discharge status
 Autonomous N (%) 47 (81%) 2 (28.6%) MWU 0.001
 O2 N (%) 8 (13.8%) 2 (28.6%)
 Ventilation N (%) 2 (3.4%) 1 (14.3%)
 Tracheostomy N (%) 1 (1.7%) 2 (28.6%)
PCFS @ 2-Month post discharge
 0 N (%) 24 (36.9%) 7 (50%) MWU 0.710
 1 N (%) 24 (36.9%) 1 (7.1%)
 2 N (%) 9 (13.8%) 1 (7.1%)
 3 N (%) 2 (3.1%) 0 (0%)
 4 N (%) 6 (9.2%) 5 (35.7%)

Categorical data are presented as frequencies and percentages (N (%)); Continuous data departing from normality assumptions and ordinal data are presented as Median with its interquartile range (1st quartile–3rd quartile) (Me [IQR]). Chi2: Chi square test; MWU: Mann–Whitney U test; PCFS: Post-COVID-19 Functional Status. For binary data, the odds ratio with its 95% confidence interval were calculated [OR (95% CI)]. FFH: Fisher–Freeman–Halton exact test. T: independent samples T test.